Pharmacologic Treatments for Sleep Disorders in Children: A Systematic Review
- 23 January 2019
- journal article
- review article
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 34 (5) , 237-247
Abstract
Sleep problems are common in children, especially those with neurodevelopmental disorders, and can lead to consequences in behavior, functioning, and quality of life. We systematically reviewed the efficacy and harms of pharmacologic treatments for sleep disorders in children and adolescents. We searched MEDLINE, Cochrane library databases, and PsycINFO through June 2018. We included 22 placebo-controlled randomized controlled trials (1-13 weeks’ duration), involving 1758 children (mean age 8.2 years). Single randomized controlled trials of zolpidem and eszopiclone in children with attention-deficit/hyperactivity disorder (ADHD) showed no improvement in sleep or ADHD ratings. Clinical Global Impression Improvement/Severity scores significantly improved with zolpidem ( P = .03 and P = .006, respectively). A single, small randomized controlled trial of diphenhydramine reported small improvements in sleep outcomes (8-10 minutes’ better sleep latency and duration) after 1 week. In 19 randomized controlled trials, melatonin significantly improved sleep latency (median 28 minutes; range 11-51 minutes), sleep duration (median 33 minutes; range 14-68 minutes), and wake time after sleep onset (range 12-43 minutes), but not number of awakenings per night (range 0-2.7). Function and behavior improvement varied. Improvement in sleep was greatest in children with autism or other neurodevelopmental disorders, and smaller in adolescents and children with chronic delayed sleep onset. Adverse events were infrequent with melatonin, but more frequent than placebo in children taking eszopiclone or zolpidem. These findings show that melatonin was useful in improving some sleep outcomes in the short term, particularly those with comorbid ASD and neurodevelopmental disorders. Other drugs and outcomes are inadequately studied.Keywords
Funding Information
- Drug Effectiveness Review Project (None)
This publication has 46 references indexed in Scilit:
- Meta-Analysis: Melatonin for the Treatment of Primary Sleep DisordersPLOS ONE, 2013
- Melatonin Treatment Effects on Adolescent Students' Sleep Timing and Sleepiness in a Placebo-Controlled Crossover StudyChronobiology International, 2012
- Methods for the Drug Effectiveness Review ProjectBMC Medical Research Methodology, 2012
- Controlled‐release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo‐controlled trialJournal of Sleep Research, 2012
- THE EFFECT OF ENGLISH-LANGUAGE RESTRICTION ON SYSTEMATIC REVIEW-BASED META-ANALYSES: A SYSTEMATIC REVIEW OF EMPIRICAL STUDIESInternational Journal of Technology Assessment in Health Care, 2012
- Dose finding of melatonin for chronic idiopathic childhood sleep onset insomnia: an RCTPsychopharmacology, 2010
- Prevalence of Diagnosed Sleep Disorders in Pediatric Primary Care PracticesPediatrics, 2010
- Exogenous melatonin for sleep problems in individuals with intellectual disability: a meta‐analysisDevelopmental Medicine & Child Neurology, 2009
- Melatonin for Chronic Insomnia in Angelman Syndrome: A Randomized Placebo-Controlled TrialJournal of Child Neurology, 2007
- A randomized, placebo‐controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilitiesJournal of Pineal Research, 2007